Search research articles
Contact Us
Filters
Showing results (51-60 of 144) with videos related to
Page
of 15
Sort By:
Zeitschrift Fur Gastroenterologie
|
October 22, 2008
[Multimodal therapy of esophageal cancer]
W Hartwig, W Hartung, O Strobel, et al.
Zeitschrift Fur Gastroenterologie
|
October 26, 2006
[ASCO update 2006--highlights of the 42. meeting of the American Society of Clinical Oncology/ASCO 2006]
A Reinacher-Schick, D Arnold, F Lordick, et al.
Der Chirurg; Zeitschrift Fur Alle Gebiete Der Operativen Medizen
|
March 3, 2006
[Curative vs palliative strategies in locoregional recurrence of gastrointestinal malignancies]
J R Siewert, F Lordick, K Ott, et al.
HNO
|
October 17, 2015
[Gene expression analyses and their possible clinical benefit in head and neck cancer]
A Dietz, M Loeffler, M Rosolowski, et al.
Leukemia
|
July 15, 2005
The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107
N von Bubnoff, S H P Gorantla, R K Kancha, et al.
British Journal of Cancer
|
June 9, 2005
Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial
S Lorenzen, J Duyster, C Lersch, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
April 17, 2014
Cisplatin- vs. oxaliplatin-based radiosensitizing chemotherapy for squamous cell carcinoma of the esophagus: a comparison of two preoperative radiochemotherapy regimens
K Fakhrian, A D Ordu, B Haller, et al.
Journal of Affective Disorders
|
January 6, 2019
The association between an anxiety disorder and cancer in medical history
N Zeynalova, S Schimpf, C Setter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 1, 2022
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
F Lordick, F Carneiro, S Cascinu, et al.
Leukemia
|
February 17, 2006
The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib
C Miething, S Feihl, C Mugler, et al.
Page
of 15
Search research articles
Search
Showing results (51-60 of 144) with videos related to
Sort By:
Page
of 15
Zeitschrift Fur Gastroenterologie
|
October 22, 2008
[Multimodal therapy of esophageal cancer]
W Hartwig, W Hartung, O Strobel, et al.
Zeitschrift Fur Gastroenterologie
|
October 26, 2006
[ASCO update 2006--highlights of the 42. meeting of the American Society of Clinical Oncology/ASCO 2006]
A Reinacher-Schick, D Arnold, F Lordick, et al.
Der Chirurg; Zeitschrift Fur Alle Gebiete Der Operativen Medizen
|
March 3, 2006
[Curative vs palliative strategies in locoregional recurrence of gastrointestinal malignancies]
J R Siewert, F Lordick, K Ott, et al.
HNO
|
October 17, 2015
[Gene expression analyses and their possible clinical benefit in head and neck cancer]
A Dietz, M Loeffler, M Rosolowski, et al.
Leukemia
|
July 15, 2005
The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107
N von Bubnoff, S H P Gorantla, R K Kancha, et al.
British Journal of Cancer
|
June 9, 2005
Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial
S Lorenzen, J Duyster, C Lersch, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
April 17, 2014
Cisplatin- vs. oxaliplatin-based radiosensitizing chemotherapy for squamous cell carcinoma of the esophagus: a comparison of two preoperative radiochemotherapy regimens
K Fakhrian, A D Ordu, B Haller, et al.
Journal of Affective Disorders
|
January 6, 2019
The association between an anxiety disorder and cancer in medical history
N Zeynalova, S Schimpf, C Setter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 1, 2022
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
F Lordick, F Carneiro, S Cascinu, et al.
Leukemia
|
February 17, 2006
The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib
C Miething, S Feihl, C Mugler, et al.
Page
of 15